Ocugen (OCGN) Competitors

Arcus Biosciences (NYSE:RCUS) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends.

Do institutionals and insiders believe in RCUS or OCGN?

92.9% of Arcus Biosciences shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 12.3% of Arcus Biosciences shares are owned by insiders. Comparatively, 4.4% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts rate RCUS or OCGN?

Arcus Biosciences presently has a consensus price target of $24.13, indicating a potential upside of 157.47%. Ocugen has a consensus price target of $6.00, indicating a potential upside of 400.00%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Ocugen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor RCUS or OCGN?

Arcus Biosciences received 85 more outperform votes than Ocugen when rated by MarketBeat users. However, 71.43% of users gave Ocugen an outperform vote while only 65.57% of users gave Arcus Biosciences an outperform vote.

Company	Underperform	Outperform
Arcus Biosciences	Outperform Votes 200 65.57%	Underperform Votes 105 34.43%
Ocugen	Outperform Votes 115 71.43%	Underperform Votes 46 28.57%

Which has more volatility & risk, RCUS or OCGN?

Arcus Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, indicating that its share price is 320% more volatile than the S&P 500.

Which has higher earnings and valuation, RCUS or OCGN?

Ocugen has lower revenue, but higher earnings than Arcus Biosciences. Ocugen is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$141M	7.04	-$307M	-$4.19	-2.24
Ocugen	$4.52M	77.50	-$63.08M	-$0.19	-6.32

Does the media favor RCUS or OCGN?

In the previous week, Arcus Biosciences had 6 more articles in the media than Ocugen. MarketBeat recorded 9 mentions for Arcus Biosciences and 3 mentions for Ocugen. Arcus Biosciences' average media sentiment score of 0.76 beat Ocugen's score of 0.74 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RCUS or OCGN more profitable?

Arcus Biosciences has a net margin of -102.66% compared to Ocugen's net margin of -532.51%. Arcus Biosciences' return on equity of -45.59% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-102.66%	-45.59%	-22.38%
Ocugen	-532.51%	-154.75%	-90.79%

Summary

Arcus Biosciences beats Ocugen on 12 of the 19 factors compared between the two stocks.